Is the price fair?
What PFE's price assumes
Pfizer trades at 37.3× earnings against 27.4× for the median Drug Manufacturers - General name, more expensive than its own group.
37.3
Trailing P/E · Drug Manufacturers - General median 27.4 · 1.36× the median: the market pays up for this one
- Price / sales
- 2.41
Price / sales · as of 2026-Q1
- Free cash flow yield
- 7.6%
Free cash flow yield · Drug Manufacturers - General median 5.8%
- Growth the price implies
- 0.00%
Growth the price implies · The price pays for 0.00% free cash flow growth a year for a decade; the business has delivered +0.99% a year over the last three.
Details›
- Price / book2026-Q1
- 1.69
- EV / sales2026-Q1
- 3.34
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - General median P/E16 names
- 27.4
- Free cash flow, trailing twelve months
- $11.0B
- Market capitalisation
- $143.7B
- 3-year revenue growth
- −7.0%
- 3-year free cash flow growth
- +0.99%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $7.12 |
| Its own P/E history, median | $9.56 |
| Its own P/E history, upper quartile | $11.33 |
| 52-week range | $22.44 – $28.57 |
| Today | $28.32 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
Ranks #14 of 16 by Smart Score